专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007140005A3 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE 审中-公开
标题翻译：脂肪酸酰胺水解酶的奥沙拉汀哌啶调节剂
公开(公告)号：WO2007140005A3
公开(公告)日：2008-01-31
申请号：PCT/US2007012631
申请日：2007-05-25
申请人： JANSSEN PHARMACEUTICA NV , APODACA RICHARD , BREITENBUCHER JAMES GUY , CHAMBERS ALISON L , SEIERSTAD MARK , XIAO WEI
发明人： APODACA RICHARD , BREITENBUCHER JAMES GUY , CHAMBERS ALISON L , SEIERSTAD MARK , XIAO WEI
IPC分类号： A01N43/76 , A61K31/42
CPC分类号： C07D413/06 , C07D413/14 , C07D471/04 , C07D491/04
摘要： Certain oxazolyl piperidine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译：描述了某些恶唑基哌啶化合物，其可用作FAAH抑制剂。此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。

2. 发明申请

WO2006074025B1 PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE 审中-公开
标题翻译：哌嗪和哌啶脲作为脂肪酸酰胺水解酶的调节剂
公开(公告)号：WO2006074025B1
公开(公告)日：2006-08-31
申请号：PCT/US2005047329
申请日：2005-12-29
申请人： JANSSEN PHARMACEUTICA NV , APODACA RICHARD , BREITENBUCHER J GUY , PATTABIRAMAN KANAKA , SEIERSTAD MARK , XIAO WEI
发明人： APODACA RICHARD , BREITENBUCHER J GUY , PATTABIRAMAN KANAKA , SEIERSTAD MARK , XIAO WEI
IPC分类号： C07D295/20 , A61P25/04 , A61P25/22 , A61P25/28 , C07C275/28 , C07D215/12 , C07D239/42 , C07D241/42 , C07D317/58 , C07D401/12 , C07D405/12 , C07D417/12
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Compounds of formula (I) : wherein, Z is -N-or>CH; R 1 is -H or -C 1-4 alkyl; Ar 1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two R a moieties; Wher each R a moiety is independently selected from the group consisting of -C 1-4 alkyl, -C 2-4 alkenyl, -OH, -OC 1-4 alkyl, halo, -CF 3 , -OCF 3 , -SCF 3 , -SH, -S(O) 0-2 C 1-4 alkyl, -OSO 2 C 1-4 alkyl, -CO 2 C 1-4 alkyl, -CO 2 H, -COC 1-4 alkyl, -N(R b )R c , -SO 2 NR b R c , -NR b SO 2 R c , -C(=O)NR b R c , -NO 2 , and -CN, wherein R b and R c are each independently -H or -C 1-4 alkyl; and Ar 2 is defined in the claims are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译：式（I）化合物：其中Z是-N-或> CH; R 1是-H或-C 1-4烷基; Ar 1是2-噻唑基，2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-环己烯基，5-嘧啶基或苯基，各自是未取代的或在碳环成员上取代的具有一个或两个R a部分; 每个R a部分独立地选自-C 1-4烷基，-C 2-4烯基，-OH ，-OC 1-4烷基，卤素，-CF 3，-OCF 3，-SCF 3， -SH，-S（O）0-2 C 1-4烷基，-OSO 2 C 1-4， C 1 -C 4烷基，-CO 2 C 1-4烷基，-CO 2 H，-COC 1-4 1-4 -N（R B） - ， - C（O）NR c R c，-CONR 2，NR b R c， -NR b，SO 2 c R c，-C（= O）NR b R c，其中R b和/或R c各自独立地为-H或-C≡N，或-C≡N， -C _{1-4 烷基; 并且权利要求中定义的Ar 2可用作FAAH抑制剂。此类化合物可用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法中。因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。}

3. 发明申请

WO2008005303A3 THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 审中-公开
标题翻译：噻唑并吡啶调节剂TRPV1
公开(公告)号：WO2008005303A3
公开(公告)日：2008-04-10
申请号：PCT/US2007015079
申请日：2007-06-28
申请人： JANSSEN PHARMACEUTICA NV , BRANSTETTER BRYAN JAMES , BREITENBUCHER JAMES GUY , LEBSACK ALEC D , XIAO WEI
发明人： BRANSTETTER BRYAN JAMES , BREITENBUCHER JAMES GUY , LEBSACK ALEC D , XIAO WEI
IPC分类号： C07D513/04 , A61K31/519 , A61P29/00
CPC分类号： C07D513/04
摘要： Certain TRPV1-modulating thiazolopyrimidine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.
摘要翻译：描述了某些TRPV1调节性噻唑并嘧啶化合物。这些化合物可以用于治疗由TRPV1活性介导的疾病状态，病症和病症的药物组合物和方法，例如疼痛，关节炎，瘙痒，咳嗽，哮喘或炎性肠病。

4. 发明申请

WO2012024581A3 OXYSTEROL COMPOUNDS 审中-公开
标题翻译： OXYSTEROL化合物
公开(公告)号：WO2012024581A3
公开(公告)日：2012-04-12
申请号：PCT/US2011048414
申请日：2011-08-19
申请人： FATE THERAPEUTICS INC , EPPERSON MATT , FAROUZ FRANCINE , STAPPENBECK FRANK , XIAO WEI
发明人： EPPERSON MATT , FAROUZ FRANCINE , STAPPENBECK FRANK , XIAO WEI
IPC分类号： C07J7/00 , A61K31/575 , A61P3/04 , A61P9/10 , A61P17/14 , A61P19/08 , A61P19/10
CPC分类号： A61K45/06 , A61K33/16 , A61K38/1841 , A61K38/1875 , A61K38/29 , A61K38/30 , C07J9/00 , C07J51/00 , A61K2300/00
摘要： Compounds for use in the treatment of bone disorders, obesity, cardiovascular disorders and neurological disorders are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Z, E, R1 and q are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
摘要翻译：公开了用于治疗骨疾病，肥胖症，心血管疾病和神经疾病的化合物。所述化合物具有以下结构（I），包括其立体异构体，药学上可接受的盐和前药，其中X，Z，E，R 1和q如本文所定义。还公开了与这些化合物的制备和使用有关的方法，以及包含这些化合物的药物组合物。

5. 发明申请

WO2008090410A3 CINNAMOMI AND PORIA COMPOSITION AND USES THEREOF 审中-公开
标题翻译： CINNAMOMI和PORIA组合物及其用途
公开(公告)号：WO2008090410A3
公开(公告)日：2008-11-13
申请号：PCT/IB2007004483
申请日：2007-10-17
申请人： JIANGSU KANION PHARMACEUTICALS , XIAO WEI , DAI XIANG LING , LING YA , WANG ZHEN ZHONG , BI YU AN , WANG ZHENG KUAN
发明人： XIAO WEI , DAI XIANG LING , LING YA , WANG ZHEN ZHONG , BI YU AN , WANG ZHENG KUAN
IPC分类号： A61K36/54
CPC分类号： A61K36/54 , A61K36/076 , A61K36/65 , A61K36/73 , A61K2236/00 , A61K2300/00
摘要： a composition comprising Chinese herbal medicines Ramulus cinnamoni and Poria cocos is provided, wherein the composition is defined by a fingerprint profile obtained from an improved chromatographic method. Various uses of such compositions are also provided.
摘要翻译：提供了包含中草药樟脑和茯苓的组合物，其中组合物由通过改进的色谱方法获得的指纹图谱定义。还提供了这些组合物的各种用途。

6. 发明申请

WO2013177067A3 HERBAL COMPOSITION FOR TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISEASES AND METHOD TO PREPARE AND USE THEREOF 审中-公开
标题翻译：用于治疗胃肠道炎症性疾病的草本组合物及其制备和使用方法
公开(公告)号：WO2013177067A3
公开(公告)日：2014-01-16
申请号：PCT/US2013041873
申请日：2013-05-20
申请人： ZHAO AIPING , ZHU KEJIN , XIAO WEI , WANG ZHENZHONG
发明人： ZHAO AIPING , ZHU KEJIN , XIAO WEI , WANG ZHENZHONG
IPC分类号： A23L33/00 , A61K9/00 , A61K36/00
CPC分类号： A61K36/535 , A61K36/232 , A61K36/284 , A61K36/53 , A61K36/752 , A61K2300/00
摘要： The present invention relates to a herbal composition to treat gastrointestinal inflammatory diseases in a subject suffering therefrom. The present invention further provides a method to use a pharmaceutical effective amount of the herbal composition to treat Gl inflammatory diseases. Particularly, this invention relates to using a pharmaceutically effective amount of the herbal composition extract having the ability to inhibit the expression of pro-inflammatory cytokines, attenuate disruption of epithelial barrier, and modulate gut function
摘要翻译：本发明涉及一种治疗患有胃肠炎性疾病的草药组合物。本发明还提供了使用药物有效量的草药组合物治疗G1炎性疾病的方法。特别地，本发明涉及使用药学有效量的具有抑制促炎细胞因子表达的能力的草药组合物提取物，减轻上皮屏障的破坏和调节肠功能

7. 发明申请

WO2012129891A3 METHOD AND SYSTEM FOR BRAKING ENERGY FEEDBACK CONTROL IN PURE ELECTRIC VEHICLE 审中-公开
标题翻译：纯电动车用能量反馈控制方法及系统
公开(公告)号：WO2012129891A3
公开(公告)日：2012-11-22
申请号：PCT/CN2011079235
申请日：2011-09-01
申请人： CHONGQING CHANGAN AUTOMOBILE , CHONGQING CHANGAN NEW ENERGY AUTOMOBILE CO LTD , ZHANG ZHENGXING , ZHOU HONGBO , TENG BO , XIAO WEI , LI XIAOYU
发明人： ZHANG ZHENGXING , ZHOU HONGBO , TENG BO , XIAO WEI , LI XIAOYU
IPC分类号： B60L7/18 , B60T8/00 , B60W10/08 , B60W10/18
CPC分类号： B60L7/18 , B60L7/26
摘要： Disclosed are a method and system for braking energy feedback control in a pure electric vehicle using a combination of electric braking and mechanical braking, with the electric braking being accomplished by controlling the operation of an electric motor in a power generating state and the mechanical braking being carried out by an electronic braking system. A vehicle control unit is the core control unit in the system for braking energy feedback control, said vehicle control unit being used for calculating the braking torque required from the electric motor and the braking force required from the electronic braking system, and for sending control commands to the control circuitry of an electric motor controller and to the electronic braking system, respectively. The present method and system satisfy the braking requirements of the vehicle under all working conditions, while also ensuring stability of vehicle operation and smoothness of vehicle braking deceleration, and at the same time enabling braking energy to be recovered in the most effective way, thus improving the overall effectiveness of vehicle energy utilization.
摘要翻译：公开了一种使用电制动和机械制动的组合在纯电动车辆中制动能量反馈控制的方法和系统，其中电制动通过控制发电状态下的电动机的操作来实现，机械制动是由电子制动系统进行。车辆控制单元是用于制动能量反馈控制的系统中的核心控制单元，所述车辆控制单元用于计算从电动机所需的制动转矩和从电子制动系统所需的制动力，并且用于发送控制命令分别到电动机控制器的控制电路和电子制动系统。本方法和系统满足车辆在所有工作条件下的制动要求，同时确保车辆运行的稳定性和车辆制动减速的平滑度，同时能够以最有效的方式回收制动能量，从而改善车辆能源利用的整体效益。

8. 发明申请

WO2012024584A3 OXYSTEROL COMPOUNDS 审中-公开
标题翻译：毒素化合物
公开(公告)号：WO2012024584A3
公开(公告)日：2012-04-12
申请号：PCT/US2011048418
申请日：2011-08-19
申请人： FATE THERAPEUTICS INC , XIAO WEI , EPPERSON MATT , FAROUZ FRANCINE , STAPPENBECK FRANK , THORSETT EUGENE
发明人： XIAO WEI , EPPERSON MATT , FAROUZ FRANCINE , STAPPENBECK FRANK , THORSETT EUGENE
IPC分类号： C07J7/00 , A61K31/575 , A61P3/04 , A61P9/10 , A61P17/14 , A61P19/08 , A61P19/10
CPC分类号： A61K45/06 , A61K33/16 , A61K38/1841 , A61K38/29 , A61K38/30 , C07J3/005 , C07J7/001 , C07J9/00 , C07J41/0055 , C07J41/0066 , C07J43/003 , C07J51/00 , A61K2300/00
摘要： Compounds for use in the treatment of bone disorders, obesity, cardiovascular disorders and neurological disorders are disclosed. The compounds have the following structure (I), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X and R1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
摘要翻译：公开了用于治疗骨骼疾病，肥胖，心血管疾病和神经障碍的化合物。所述化合物具有以下结构（I），其包括立体异构体，其药学上可接受的盐和前药，其中X和R 1如本文所定义。还公开了与这种化合物的制备和使用相关的方法以及包含这些化合物的药物组合物。

9. 发明申请

WO2010043410A3 METHOD FOR INFORMATION INTERACTION AND SECURE DEVICE 审中-公开
标题翻译：信息交互和安全设备的方法
公开(公告)号：WO2010043410A3
公开(公告)日：2010-10-07
申请号：PCT/EP2009007447
申请日：2009-10-16
申请人： GIESECKE & DEVRIENT GMBH , XIAO WEI , ZHU SHIFENG , GENG TONG
发明人： XIAO WEI , ZHU SHIFENG , GENG TONG
IPC分类号： G06F21/34 , G06F21/60 , G06F21/64 , H04L29/06
CPC分类号： H04L63/0853 , G06F21/34 , G06F21/602 , G06F21/64 , H04L63/0428 , H04L63/145
摘要： The invention relates to a method for information interaction and a secure device. The method includes the steps: receive an operation command from a client and input the operating information according to the said operation command; judge whether the client user confirms the operating information, if a judgment results in YES, operating information is encrypted and send to client. By inputting operating information or authentication password and sending the encrypted information on the network, the operating information or data is kept secure and a spam or virus has no way to attack the data. The invented secure device includes: a receiver unit, a judge unit, an encryption unit and a sending unit. So the secure device solves the problem in the on-line transaction deal.
摘要翻译：本发明涉及一种用于信息交互的方法和一种安全装置。该方法包括以下步骤：从客户接收操作命令并根据所述操作命令输入操作信息; 判断客户端用户是否确认操作信息，判断结果为是，操作信息被加密并发送给客户端。通过输入操作信息或认证密码并在网络上发送加密信息，操作信息或数据保持安全，垃圾邮件或病毒无法攻击数据。本发明的安全装置包括：接收单元，判断单元，加密单元和发送单元。因此，安全设备解决了在线交易协议中的问题。

10. 发明申请

WO9921845A2 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES 审中-公开
标题翻译： 4-氨基噻唑衍生物，它们的制备及其作为依赖于细胞周期蛋白依赖性激酶的抑制剂的用途
公开(公告)号：WO9921845A2
公开(公告)日：1999-05-06
申请号：PCT/US9822809
申请日：1998-10-27
申请人： AGOURON PHARMA , CHONG WESLEY K M , CHU SHAO SONG , DUVADIE ROHIT R , LI LIN , XIAO WEI , YANG YI
发明人： CHONG WESLEY K M , CHU SHAO SONG , DUVADIE ROHIT R , LI LIN , XIAO WEI , YANG YI
IPC分类号： C07D277/20 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/551 , A61P35/00 , A61P43/00 , C07D213/00 , C07D235/00 , C07D277/42 , C07D277/56 , C07D333/00 , C07D417/06 , C07D417/12 , C07D417/14 , C07D521/00 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D277/42 , C07D417/06 , C07D417/12 , C07D417/14
摘要： This invention is directed to aminothiazole compounds of formula (I) wherein R is a substituted or unsubstituted group selected from: C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.
摘要翻译：本发明涉及式（I）的氨基噻唑化合物，其中R 1是取代或未取代的选自以下的基团：C 1-6 - 烷基; C 1-6 - 链烯基; C 1-6 - 炔基; C 1-6 - 烷氧基取代; C 1-6 - 醇; 碳环或杂环，单环或稠合或非稠合多环，环烷基; 碳环或杂环，单环或稠合或非稠合多环，芳基; 羰; 醚; （C 1-6 - 烷基）羰基; （C 1-6 - 烷基） - 芳基; （C 1-6 - 烷基） - 环烷基; （C 1-6 - 烷基） - （C 1-6 - 烷氧基）; 芳基 - （C 1-6 - 烷氧基）; 硫醚; 巯基; 和磺酰基; 其中当R 1被取代时，每个取代基独立地为卤素; 卤代; C 1-6 - 烷基; C 1-6 - 链烯基; C 1-6 - 炔基; 羟; C 1-6 - 烷氧基取代; 氨基; 硝基; 巯基; 硫醚; 亚胺; 氰基; 酰胺基; 膦酸; 膦; 羧基; 硫代羰基; 磺酰基; 磺胺; 酮; 醛; 酯; 氧; 碳环或杂环，单环或稠合或非稠合多环，环烷基; 或碳环或杂环，单环或稠合或非稠合的多环芳基; 并且R 2是碳环或杂环的单环或稠合或非稠合的多环环结构，其在与连接点相邻的位置上具有取代基，该环结构任选进一步被取代，其中R 2的每个取代基 >独立地为卤素; 卤代; C 1-6 - 烷基; C 1-6 - 链烯基; C 1-6 - 炔基; 羟; C 1-6 - 烷氧基取代; 氨基; 硝基; 巯基; 硫醚; 亚胺; 氰基; 酰胺基; 膦酸; 膦; 羧基; 硫代羰基; 磺酰基; 磺胺; 酮; 醛; 酯; 氧; 碳环或杂环，单环或稠合或非稠合多环，环烷基; 或碳环或杂环，单环或稠合或非稠合的多环芳基; 或式（I）化合物的药学上可接受的盐，或式（I）化合物或其药学上可接受的盐的前药或药学活性代谢物用于抑制细胞周期蛋白依赖性激酶（CDK）如CDK1，CDK2 ，CDK4和CDK6。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途以及通过施用有效量的这些化合物治疗恶性肿瘤和其他病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式